Epoch Investment Partners Inc. raised its position in shares of CONMED Corporation (NASDAQ:CNMD) by 2.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 232,576 shares of the medical technology company’s stock after purchasing an additional 4,839 shares during the quarter. Epoch Investment Partners Inc. owned approximately 0.83% of CONMED worth $12,203,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in CNMD. Teachers Advisors LLC increased its position in CONMED by 3.8% during the 1st quarter. Teachers Advisors LLC now owns 46,825 shares of the medical technology company’s stock valued at $2,079,000 after purchasing an additional 1,702 shares during the period. Renaissance Technologies LLC acquired a new stake in CONMED during the 1st quarter valued at approximately $1,887,000. Aperio Group LLC increased its position in CONMED by 10.7% during the 2nd quarter. Aperio Group LLC now owns 5,034 shares of the medical technology company’s stock valued at $256,000 after purchasing an additional 487 shares during the period. Strs Ohio bought a new position in shares of CONMED during the 2nd quarter worth approximately $967,000. Finally, Municipal Employees Retirement System of Michigan boosted its holdings in shares of CONMED by 3.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 5,850 shares of the medical technology company’s stock worth $298,000 after buying an additional 220 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Luke A. Pomilio sold 29,363 shares of the stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $50.70, for a total value of $1,488,704.10. Following the transaction, the executive vice president now directly owns 45,486 shares in the company, valued at approximately $2,306,140.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Luke A. Pomilio sold 12,429 shares of the stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $50.63, for a total value of $629,280.27. Following the completion of the transaction, the chief financial officer now owns 45,486 shares in the company, valued at $2,302,956.18. The disclosure for this sale can be found here. Over the last quarter, insiders sold 51,812 shares of company stock worth $2,654,756. 2.62% of the stock is owned by company insiders.
CONMED (NASDAQ:CNMD) last posted its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. CONMED had a return on equity of 8.40% and a net margin of 1.99%. The firm had revenue of $190.10 million for the quarter, compared to analysts’ expectations of $187.13 million. During the same period in the prior year, the business earned $0.41 EPS. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. sell-side analysts anticipate that CONMED Corporation will post 1.86 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, January 5th. Investors of record on Friday, December 15th will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.54%. The ex-dividend date of this dividend is Thursday, December 14th. CONMED’s dividend payout ratio is currently 142.86%.
A number of equities analysts have issued reports on the company. Piper Jaffray Companies restated a “hold” rating and set a $46.00 price target on shares of CONMED in a report on Friday, November 3rd. BidaskClub cut CONMED from a “sell” rating to a “strong sell” rating in a report on Sunday, August 20th. Needham & Company LLC restated a “buy” rating and set a $58.00 price target on shares of CONMED in a report on Friday, November 17th. Zacks Investment Research cut CONMED from a “hold” rating to a “sell” rating in a report on Monday, November 6th. Finally, KeyCorp restated a “hold” rating on shares of CONMED in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $50.67.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/07/conmed-corporation-cnmd-holdings-increased-by-epoch-investment-partners-inc.html.
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.